Journal
ORAL ONCOLOGY
Volume 58, Issue -, Pages 59-70Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.oraloncology.2016.05.002
Keywords
Immunity; Antigenicity; Immunogenicity; Immunotherapy
Categories
Funding
- Intramural NIH HHS [ZIA DC000087-01] Funding Source: Medline
- NIDCD NIH HHS [R01 DC000087] Funding Source: Medline
Ask authors/readers for more resources
A significant subset of head and neck cancers display a T-cell inflamed phenotype, suggesting that patients with these tumors should respond to therapeutic approaches aimed at strengthening antitumor immune responses. A major barrier to the development of an effective anti-tumor immune response, at baseline or in response to immunotherapy, is the development of an immunosuppressive tumor microenvironment. Several well described mechanisms of effector immune cell suppression in the head and neck cancer microenvironment are discussed here, along with updates on current trials designed to translate what we have learned from pre-clinical and correlative clinical studies into improved responses in patients with head and neck cancer following immune activating therapies. Published by Elsevier Ltd.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available